Chemotherapy-Induced Anemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type (Mild Anemia, Moderate Anemia, Severe Anemia), By Treatment Type (RBC Transfusions, Erythropoiesis-stimulating agents (ESAs), Iron Supplementation), By Drug Type (Epogen Injection, Procrit Injection, Androxy Oral, Aranesp injection, Epoetin Alfa Injection, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 2.86 Billion
CAGR (2026-2031)	7.16%
Fastest Growing Segment	Epoetin Alfa Injection
Largest Market	North America
Market Size (2031)	USD 4.33 Billion

Market Overview

The Global Chemotherapy-Induced Anemia Market will grow from USD 2.86 Billion in 2025 to USD 4.33 Billion by 2031 at a 7.16% CAGR. Chemotherapy-induced anemia therapeutics encompass erythropoiesis stimulating agents, iron supplements, and red blood cell transfusions designed to counteract low hemoglobin levels in patients undergoing myelosuppressive cancer treatment. The primary factor propelling market trajectory is the rising global prevalence of oncological conditions requiring aggressive cytotoxic protocols that deplete red blood cell counts. According to the American Cancer Society, in 2025, approximately 2,041,910 new cancer cases were projected to occur in the United States, indicating a sustained and expanding patient pool necessitating anemia management.

However, the sector encounters substantial impediments regarding the safety profile of existing pharmaceutical options. Stringent regulatory guidelines and black box warnings associated with erythropoiesis stimulating agents regarding increased risks of cardiovascular events and potential tumor progression restrict their unrestricted utilization. These safety concerns necessitate conservative dosing strategies and often lead healthcare providers to seek alternative management routes, thereby restraining the overall revenue potential of the global market.

Key Market Drivers

The escalating global incidence of oncological malignancies serves as a primary catalyst for the chemotherapy-induced anemia market, as rising cancer rates necessitate increased utilization of myelosuppressive therapies. This expanding patient pool requires sustained supportive care interventions, including erythropoiesis-stimulating agents and iron replacement therapies, to manage hemoglobin levels and maintain treatment schedules. According to the International Agency for Research on Cancer, February 2024, in the 'Global cancer burden growing' press release, over 35 million new cancer cases are predicted in 2050, representing a 77% increase from the estimated 20 million cases in 2022. Such demographic shifts demand scalable anemia management protocols to ensure patient adherence to aggressive cytotoxic regimens, thereby directly driving volume growth for therapeutic manufacturers.

Simultaneously, a robust clinical pipeline of novel mechanism-of-action therapeutics is advancing the sector by offering treatments that reduce transfusion dependence and address the safety limitations of legacy options. Developers are commercializing agents targeting specific pathways in bone marrow failure, thereby diversifying available management strategies beyond traditional erythropoietin production. For instance, according to Geron Corporation, June 2024, in the 'Geron Announces FDA Approval of Rytelo' press release, the regulatory body approved imetelstat for treating transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes. This continued innovation supports broader market expansion and accessibility, as evidenced by the performance of related therapeutic categories. According to Sandoz, in 2024, net sales in the biosimilars segment grew 29% in constant currencies during the first half of the year, underscoring the expanding commercial footprint of supportive oncology therapeutics.

Download Free Sample Report

Key Market Challenges

The substantial impediments regarding the safety profile of erythropoiesis-stimulating agents constitute a critical challenge restricting the expansion of the Global Chemotherapy-Induced Anemia Market. Regulatory agencies have mandated rigorous black box warnings highlighting increased risks of severe cardiovascular events and potential tumor progression associated with these therapeutics. These safety concerns compel healthcare providers to adopt highly conservative prescribing behaviors, often limiting treatment to only the most severe cases or avoiding pharmaceutical intervention entirely in favor of observation. This regulatory strictness directly hampers market growth by artificially suppressing the volume of prescriptions and narrowing the addressable patient population.

Consequently, this cautious clinical environment results in a significant rate of under-treatment, where the market fails to capture the full scope of patient demand. This trend is substantiated by recent clinical data showing a gap between disease prevalence and therapeutic uptake. According to the National Comprehensive Cancer Network, in 2024, an analysis of patients with solid tumors revealed that although 44% experienced anemia within six months of diagnosis, fewer than 40% of those affected received any form of directed treatment. Such low intervention rates demonstrate how safety-driven barriers actively constrain therapeutic utilization and limit the overall revenue potential of the sector.

Key Market Trends

The growing adoption of cost-effective biosimilar erythropoiesis-stimulating agents is fundamentally reshaping the market landscape as healthcare providers prioritize financial sustainability without compromising clinical outcomes. Patent expirations for originator biologics have catalyzed a market shift, prompting payers and institutions to mandate the utilization of value-based biosimilars for managing chemotherapy-induced anemia. This transition is driven by the urgent need to mitigate the high economic burden associated with oncology supportive care, leading to aggressive formulary adjustments that favor these lower-cost alternatives. According to Amgen, February 2025, in the 'Amgen Reports Fourth Quarter and Full Year 2024 Financial Results', sales of its established products portfolio, including Epogen and Aranesp, decreased 19% for the full year 2024, primarily driven by volume declines and lower net selling prices resulting from intense biosimilar competition.

Simultaneously, there is a rising preference for intravenous iron therapies, often utilized in combination with erythropoiesis-stimulating agents or as a standalone intervention, to enhance hemoglobin response and mitigate safety risks. Clinical protocols are increasingly integrating intravenous iron to optimize iron stores rapidly, which addresses the functional iron deficiency common in oncology patients and reduces the overall dependence on red blood cell transfusions. This approach allows practitioners to lower the dosage of stimulating agents, thereby minimizing cardiovascular risks while maintaining therapeutic efficacy. According to CSL Limited, August 2024, in the 'CSL Annual Report 2024', the intravenous iron market is positioned for continued volume growth as approximately 85% of eligible patients currently do not receive intravenous iron treatment, highlighting a significant untapped opportunity for therapeutic expansion.

Segmental Insights

The Epoetin Alfa Injection segment represents the fastest-growing category within the Global Chemotherapy-Induced Anemia Market. This rapid expansion is largely attributed to the increasing approval and adoption of cost-effective biosimilars, which have significantly broadened patient access to essential treatments. Regulatory authorities such as the U.S. FDA have validated these therapeutic options, encouraging healthcare providers to utilize them for managing low hemoglobin levels in oncology patients. Consequently, the proven ability of Epoetin Alfa to effectively reduce the clinical dependence on red blood cell transfusions continues to drive its accelerated market demand.

Regional Insights

North America maintains a leading position in the global Chemotherapy-Induced Anemia market, driven primarily by the rising prevalence of cancer and a highly developed healthcare infrastructure. The region benefits significantly from favorable reimbursement policies and substantial healthcare expenditure, which ensure broad patient access to essential anemia therapies. Additionally, the United States Food and Drug Administration actively supports market stability through the clear regulation and approval of Erythropoiesis-Stimulating Agents and biosimilars. This strong regulatory framework, combined with the presence of key pharmaceutical manufacturers, reinforces the region's continued dominance in this therapeutic sector.

Recent Developments

• In May 2025, Zydus Lifesciences Limited received a positive recommendation from the Subject Expert Committee of the Central Drugs Standard Control Organisation to conduct a Phase III clinical trial for desidustat. The regulatory authority granted permission to assess the efficacy and safety of a 120 mg dosage of the oral hypoxia-inducible factor prolyl hydroxylase inhibitor specifically for treating chemotherapy-induced anemia in patients with solid tumors. This regulatory milestone enabled the company to advance the clinical development of the drug for a new oncology indication, expanding its potential therapeutic application beyond the treatment of anemia associated with chronic kidney disease.
• In February 2025, AstraZeneca entered into a definitive agreement to acquire FibroGen’s subsidiary in China, securing full global rights to the anemia medication roxadustat in that region. The transaction, valued at approximately $160 million, consolidated the development and commercialization operations for the drug, which was under regulatory review by the National Medical Products Administration for the treatment of chemotherapy-induced anemia. This acquisition allowed the pharmaceutical giant to integrate the asset into its broader oncology and supportive care portfolio, aiming to maximize the commercial potential of the therapy for cancer patients experiencing anemia across the Chinese market.
• In October 2024, detailed results from a pivotal Phase 3 clinical trial evaluating roxadustat for the treatment of chemotherapy-induced anemia were published in a prominent oncology journal. The study, sponsored by FibroGen, Inc., investigated the efficacy and safety of the oral hypoxia-inducible factor prolyl hydroxylase inhibitor compared to a standard injectable erythropoiesis-stimulating agent in patients with non-myeloid malignancies. The data demonstrated that the drug met the primary efficacy endpoint of non-inferiority regarding the change in hemoglobin levels from baseline. This research highlighted the therapeutic potential of the oral agent to provide a convenient treatment alternative for cancer patients suffering from anemia.
• In August 2024, Pharmacosmos A/S announced a definitive agreement to acquire G1 Therapeutics, Inc. for a total equity value of approximately $405 million. This strategic acquisition included the rights to trilaciclib, a first-in-class FDA-approved therapy designed to proactively reduce chemotherapy-induced myelosuppression, which encompasses complications such as anemia, neutropenia, and thrombocytopenia. The merger was structured to utilize Pharmacosmos’s established commercial presence in hematology and supportive care to accelerate the availability of the drug. The company aimed to address the burden of chemotherapy-induced cytopenias and improve patient outcomes in the extensive-stage small cell lung cancer market.

Key Market Players

• Dr. Reddy's Laboratories Ltd.
• Pfizer Inc.
• Panacea Biotec Limited
• SBI Pharmaceuticals Co., Ltd
• Sumitomo Dainippon Pharma Co., Ltd.
• PharmaEssentia Corp.
• PhytoHealth Corp
• UBI Pharma Inc.
• Amgen Inc.
• Astellas Pharma Inc.

By Disease Type	By Treatment Type	By Drug Type	By End User	By Region
Mild Anemia Moderate Anemia Severe Anemia	RBC Transfusions Erythropoiesis-stimulating agents (ESAs) Iron Supplementation	Epogen Injection Procrit Injection Androxy Oral Aranesp injection Epoetin Alfa Injection Others	Hospitals & Clinics Ambulatory Care Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Chemotherapy-Induced Anemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Chemotherapy-Induced Anemia Market, By Disease Type:

• Mild Anemia
• Moderate Anemia
• Severe Anemia

• Chemotherapy-Induced Anemia Market, By Treatment Type:

• RBC Transfusions
• Erythropoiesis-stimulating agents (ESAs)
• Iron Supplementation

• Chemotherapy-Induced Anemia Market, By Drug Type:

• Epogen Injection
• Procrit Injection
• Androxy Oral
• Aranesp injection
• Epoetin Alfa Injection
• Others

• Chemotherapy-Induced Anemia Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

• Chemotherapy-Induced Anemia Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE